A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In patients with otitis media presenting with otoscopy-confirmed otorrhea who had
tympanostomy tube insertion or tympanic perforation, to evaluate the safety, tolerability,
and the proportion of patients with cessation of otorrhea after ear-drop administration of
YH1177 or YH1177-D for 14 days and therefore to determine the optimal clinical dose.